I would add a biologic agent, likely a TNF inhibitor or abatacept. As with any patient with active RA, it would be important to add therapy that controls their disease activity, as well as allowing them to reduce or preferentially discontinue steroids. I would avoid other agents with known risk for ...

In the early and mid-1990s, 2 RCTs examined the use of MTX with AZA in RA. Both found that the combination was not more effective than MTX alone, and MTX monotherapy led to better responses than AZA or the combo. AEs were more common with combo and AZA monotherapy; reasons for discontinuation includ...